Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory A Otterson

Showing results (1-10 of 157) with videos related to

Pageof 16
Sort By:
Current Medicinal Chemistry. Anti-Cancer Agents|May 29, 2003
The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cellsWei-Guo Zhu, Gregory A Otterson
Drugs in Context|July 2, 2019
Immunotherapy in inoperable stage III non-small cell lung cancer: a reviewNatasha A Jain, Gregory A Otterson
Clinical Lung Cancer|July 7, 2016
Incorporation of Antiangiogenic Therapy Into the Non-Small-Cell Lung Cancer ParadigmBenjamin F Chu, Gregory A Otterson
Expert Opinion on Investigational Drugs|June 25, 2011
Romidepsin: a novel histone deacetylase inhibitor for cancerErin M Bertino, Gregory A Otterson
Lung Cancer (Amsterdam, Netherlands)|October 5, 2010
Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancerErin M Bertino, Gregory A Otterson
Drugs in Context|March 23, 2019
Agents to treat <i>BRAF-</i>mutant lung cancerJean G Bustamante Alvarez, Gregory A Otterson
Trends in Genetics : TIG|August 8, 2007
Unraveling the epigenetic code of cancer for therapyLaura T Smith, Gregory A Otterson, Christoph Plass
Photomedicine and Laser Surgery|September 26, 2012
Photodynamic therapy (PDT) may provide effective palliation in the treatment of primary tracheal carcinoma: a small case seriesLudmila Katherine Martin, Gregory A Otterson, Tanios Bekaii-Saab
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 28, 2010
Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304)Gregory A Otterson, Lydia Hodgson, Herbert Pang, et al.
Cancer|February 27, 2023
Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancerLiza C Villaruz, George R Blumenschein, Gregory A Otterson, et al.
Pageof 16

Showing results (1-10 of 157) with videos related to

Sort By:
Pageof 16
Current Medicinal Chemistry. Anti-Cancer Agents|May 29, 2003
The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cellsWei-Guo Zhu, Gregory A Otterson
Drugs in Context|July 2, 2019
Immunotherapy in inoperable stage III non-small cell lung cancer: a reviewNatasha A Jain, Gregory A Otterson
Clinical Lung Cancer|July 7, 2016
Incorporation of Antiangiogenic Therapy Into the Non-Small-Cell Lung Cancer ParadigmBenjamin F Chu, Gregory A Otterson
Expert Opinion on Investigational Drugs|June 25, 2011
Romidepsin: a novel histone deacetylase inhibitor for cancerErin M Bertino, Gregory A Otterson
Lung Cancer (Amsterdam, Netherlands)|October 5, 2010
Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancerErin M Bertino, Gregory A Otterson
Drugs in Context|March 23, 2019
Agents to treat <i>BRAF-</i>mutant lung cancerJean G Bustamante Alvarez, Gregory A Otterson
Trends in Genetics : TIG|August 8, 2007
Unraveling the epigenetic code of cancer for therapyLaura T Smith, Gregory A Otterson, Christoph Plass
Photomedicine and Laser Surgery|September 26, 2012
Photodynamic therapy (PDT) may provide effective palliation in the treatment of primary tracheal carcinoma: a small case seriesLudmila Katherine Martin, Gregory A Otterson, Tanios Bekaii-Saab
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 28, 2010
Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304)Gregory A Otterson, Lydia Hodgson, Herbert Pang, et al.
Cancer|February 27, 2023
Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancerLiza C Villaruz, George R Blumenschein, Gregory A Otterson, et al.
Pageof 16